Source: RealWire
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development…
For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire…
TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE: BTTR) (“Better…
KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”),…
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the…
World-leading authorities explore the potential for extending human lifespan on Monday, March 10 at the JW…